PathMaker Neurosystems Inc. Announces Two Key Technology Patents Granted by US Patent and Trademark Office
Boston, MA (September 15, 2015) — PathMaker Neurosystems Inc. (“PathMaker”), a clinical-stage neuromodulation company developing non-invasive neurotherapy systems for the treatment of patients with neuromotor disorders, announced today that the United States Patent and Trademark Office (US PTO) has granted two fundamental patents covering its methods and systems for treating patients with neuromotor disorders. The issued patents (US Patent 9,011,310 and US Patent 9,008,781) broadly cover our Company’s proprietary TripleStim™ technology that is the basis of a new generation of non-invasive neurotherapy systems being developed by PathMaker Neurosystems.
TripleStim utilizes a non-invasive combination of simultaneous cortical, spinal and peripheral stimulations that amplify descending signals going from brain to muscle. TripleStim is the basis of our MyoAmplifier PM-3300 system, in development for the treatment of paralysis and muscle weakness in patients with stroke, cerebral palsy (CP), multiple sclerosis (MS), spinal cord injury (SCI), traumatic brain injury (TBI) and numerous other neurological conditions. These patients often have chronic disabilities that severely limit motor control, muscle function and mobility, and there is a huge unmet need for effective therapies that can safely and durably reverse these chronic conditions.
“We are gratified with these issuances and expect a continued flow of patent approvals,” said Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of PathMaker. “These patent successes are built upon a fundamentally novel and breakthrough approach to modulating spinal circuits and descending pathways.”
About PathMaker Neurosystems Inc.
PathMaker Neurosystems Inc. is a clinical-stage neuromodulation company founded to commercialize recent breakthrough advances in the development and clinical application of trans-spinal direct current stimulation (tsDCS) for patients with neuromotor disorders. More than 27 million patients in the US and Europe suffer disabilities due to stroke, cerebral palsy, multiple sclerosis, spinal cord injury, traumatic brain injury, Parkinson’s disease and other neurological disorders. The breakthrough non-invasive systems that PathMaker is developing are opening up a new era of non-invasive neurotherapy for patients suffering from chronic neuromotor conditions.
Press Contact: Don Goncalves, Tiziani Whitmyre, 781.793.9380, email@example.com